Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease

News   Apr 07, 2010

 
Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease
 
 
 

RELATED ARTICLES

Patent Plausability Case Sees BIA Intervention

News

The UK Bioindustry Association (BIA) will intervene in a court case which could have huge ramifications for UK bioscience.

READ MORE

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

Tweak to Technique Could Bolster Disease Detection

News

A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE